Войти в систему Зарегистрироваться бесплатно

Hutchison China MediTech Денежные средства на акцию

Что обозначает Денежные средства на акцию в Hutchison China MediTech?

Денежные средства на акцию Hutchison China MediTech Ltd. является 92.74

Какое определение для Денежные средства на акцию?

Денежные средства на акцию - это наличные денежные средства компании, поделенные на акции компании в обращении.

Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.

When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.

Денежные средства на акцию компаний в Health Care сектор на LSE по сравнению с Hutchison China MediTech

Что делает Hutchison China MediTech?

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.

Компании с денежные средства на акцию похож на Hutchison China MediTech



  • MOIL имеет Денежные средства на акцию из 91.95
  • Sree Rayalaseema Hi-Strength Hypo имеет Денежные средства на акцию из 92.01
  • Aditya Birla Money имеет Денежные средства на акцию из 92.05
  • Apollo Hospitals Enterprise имеет Денежные средства на акцию из 92.33
  • Alpha Real Trust имеет Денежные средства на акцию из 92.57
  • TTK Healthcare имеет Денежные средства на акцию из 92.62
  • Hutchison China MediTech имеет Денежные средства на акцию из 92.74
  • NBCC (India) имеет Денежные средства на акцию из 92.92
  • IndusInd Bank имеет Денежные средства на акцию из 93.05
  • Twentyfour Income Fund имеет Денежные средства на акцию из 93.11
  • VA Tech Wabag имеет Денежные средства на акцию из 93.24
  • MaxCyte имеет Денежные средства на акцию из 93.32
  • MM Forgings имеет Денежные средства на акцию из 93.85